AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development With a grant of USD 475,000, the Michael J. Fox Basis is funding preclinical advancement of a vaccine against Parkinson’s disease by AFFiRiS AG. The vaccine, referred to as PD01, targets the protein alpha-synuclein and may offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson’s disease generic levitra . The basis of PD01 may be the company’s AFFITOME technology, which already delivered, among others, two vaccines from AFFiRiS AG for the treating Alzheimer’s disease.
However, fitting at the moment of President Reagan’s centennial celebration, major advancements are unfolding. Of enormous significance, the latest establishment of the National Alzheimer’s Disease Project, using its charge to coordinate federal government efforts to avoid and treat the disease and create a national technique to defeat it, holds much promise. As we celebrate President Reagan’s 100th birthday, let’s look to the generous spirit of the President’s open public acknowledgement of Alzheimer’s disease as motivation for the country to steadfastly move forward to conquer this heartbreaking disease.